Market Overview:
The recombinant DNA vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The recombinant DNA vaccine market is segmented on the basis of type, application, and region. On the basis of type, the recombinant DNA vaccine market is segmented into recombinant protein vaccines and gene-based vaccines. Recombinant protein vaccines are further sub-segmented into viral vector-based vaccines and non-viral vector based vaccines. Gene-based vaccines are further sub-segmented into naked plasmid DNA (pDNA) vaccine and virus like particle (VLP) vaccine. On the basis of application, the recombinant DNA vaccine market is segmented into human applications and animal applications.
Product Definition:
A recombinant DNA vaccine is a vaccine created from recombinant DNA technology. Recombinant DNA vaccines are made from pieces of genetic code from different viruses, bacteria, or other organisms. These pieces of code are inserted into cells that can produce proteins. When the cells produce these proteins, they also produce immunity against the disease.
Recombinant Protein Vaccine:
Recombinant protein vaccine is a new type of vaccine that uses the body's own immune cells to fight off diseases. These vaccines are made from living organisms and can stimulate the human body's immune system to produce antibodies without causing the disease itself. The most common way of producing recombinant proteins is by using an expression system, which allows for production of any recombinant protein in E.coli bacteria cell culture.
Gene-Based Vaccine:
The global gene-based vaccine and its usage in recombinant DNA vaccine market size was valued at USD 6.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of infectious diseases such as HIV, cancer, & other autoimmune diseases coupled with rising demand for better healthcare services are some major factors driving the growth of this industry globally.
Application Insights:
On the basis of application, the global market is segmented into human and animal. The human application segment dominated the overall market in terms of revenue share in 2017. This can be attributed to growing concerns about diseases carried by humans that are able to be transmitted via blood or body fluids. These include HIV, hepatitis A & B, influenza virus among others.
The animal application segment is expected to witness a lucrative CAGR during the forecast period owing to rising incidences of disease outbreaks among animals such as poultry and livestock across various regions including Asia Pacific and Middle East & Africa countries such as Saudi Arabia UAE Oman Pakistan etc., which leads towards increasing demand for vaccines for these animals from 2018 to 2030.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a substantial number of companies, which are engaged in developing and commercializing rDNA vaccines. The U.S., being one of the developed economies, has a well-established healthcare infrastructure that makes it easier for new technologies to gain acceptance and utilization across the country.
On account of contrary political situations among various countries such as Russia-Ukraine conflict & civil war; Middle East crisis; terrorism problems in Africa etc.
Growth Factors:
- Increasing prevalence of chronic diseases: The global recombinant DNA vaccine market is expected to grow at a CAGR of over 16% during the forecast period. This can be attributed to the increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders.
- Technological advancements: The development of novel recombinant DNA vaccines is expected to drive the growth of this market in the coming years. These vaccines are more effective than traditional ones and cause fewer side effects.
- Rising demand for preventive healthcare: There is a growing demand for preventive healthcare services across the globe due to rising awareness about health risks among people. This is likely to boost the growth of the recombinant DNA vaccine market in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant DNA Vaccine Market Research Report
By Type
Recombinant Protein Vaccine, Gene-Based Vaccine
By Application
Human, Animal
By Companies
Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant DNA Vaccine Market Report Segments:
The global Recombinant DNA Vaccine market is segmented on the basis of:
Types
Recombinant Protein Vaccine, Gene-Based Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human, Animal
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GSK
- Sanofi
- Zoties
- Elanco
- Boehringer-Ingelheim
- Indian Immunologicals
- Plumbline Life Sciences
Highlights of The Recombinant DNA Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Protein Vaccine
- Gene-Based Vaccine
- By Application:
- Human
- Animal
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant DNA Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant DNA vaccines are vaccines made from pieces of DNA that have been recombined or “recombinant” so that they can produce an immunity response in a different animal. Recombinant DNA vaccine technology is used to create new types of vaccines, which can be more effective and specific than traditional vaccine methods.
Some of the major players in the recombinant dna vaccine market are Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences.
The recombinant dna vaccine market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant DNA Vaccine Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Recombinant DNA Vaccine Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Recombinant DNA Vaccine Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Recombinant DNA Vaccine Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Recombinant DNA Vaccine Market Size & Forecast, 2020-2028 4.5.1 Recombinant DNA Vaccine Market Size and Y-o-Y Growth 4.5.2 Recombinant DNA Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Recombinant Protein Vaccine
5.2.2 Gene-Based Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Human
6.2.2 Animal
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant DNA Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant DNA Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Recombinant Protein Vaccine
9.6.2 Gene-Based Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Human
9.10.2 Animal
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Recombinant Protein Vaccine
10.6.2 Gene-Based Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Human
10.10.2 Animal
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Recombinant Protein Vaccine
11.6.2 Gene-Based Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Human
11.10.2 Animal
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Recombinant Protein Vaccine
12.6.2 Gene-Based Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Human
12.10.2 Animal
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Recombinant Protein Vaccine
13.6.2 Gene-Based Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Human
13.10.2 Animal
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant DNA Vaccine Market: Competitive Dashboard
14.2 Global Recombinant DNA Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 GSK
14.3.3 Sanofi
14.3.4 Zoties
14.3.5 Elanco
14.3.6 Boehringer-Ingelheim
14.3.7 Indian Immunologicals
14.3.8 Plumbline Life Sciences